<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5286-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATOXIA 90 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Etoricoxib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Pharmacotherapeutic group:<br />ATOXIA&reg; contains the active substance etoricoxib. ATOXIA&reg; is one of a group of medicines called selective COX-2 inhibitors. These belong to a family of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).<br />- Therapeutic indications:<br />- ATOXIA&reg; helps to reduce the pain and swelling (inflammation) in the joints and muscles of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout.<br />- ATOXIA&reg; is also used for the short term treatment of moderate<br />pain after dental surgery in people 16 years of age and older.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take ATOXIA&reg;</strong><br />&bull; If you are allergic (hypersensitive) to etoricoxib or any of the other ingredients of this<br />&bull; If you are allergic to non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors<br />&bull; If you have a current stomach ulcer or bleeding in your stomach or intestines<br />&bull; If you have serious liver disease<br />&bull; If you have serious kidney disease<br />&bull; If you are or could be pregnant or are breast-feeding<br />&bull; If you are under 16 years of age<br />&bull; If you have inflammatory bowel disease, such as Crohn&rsquo;s Disease,<br />Ulcerative Colitis, or Colitis<br />&bull; If you have high blood pressure that has not been controlled by treatment (check with your doctor or nurse if you are not sure whether your blood pressure is adequately controlled)<br />&bull; If your doctor has diagnosed heart problems including heart failure (moderate or severe types), angina (chest pain)<br />&bull; If you have had a heart attack, bypass surgery, peripheral arterial<br />disease (poor circulation in legs or feet due to narrow or blocked arteries)<br />&bull; If you have had any kind of stroke (including mini-stroke, transient<br />ischaemic attack or TIA). Etoricoxib may slightly increase your risk of heart attack and stroke and this is why it should not be used in those who have already had heart problems or stroke.<br />If you think any of these are relevant to you, do not take the&nbsp;tablets until you have consulted your doctor.<br /><strong>b. Take special care with ATOXIA&reg;</strong><br />Talk to your doctor or pharmacist before taking ATOXIA&reg;<br />&bull; You have a history of stomach bleeding or ulcers.<br />&bull;You are dehydrated, for example by a prolonged bout of vomiting<br />or diarrhoea.<br />&bull; You have swelling due to fluid retention.<br />&bull; You have a history of heart failure, or any other form of heart disease.<br />&bull; You have a history of high blood pressure. ATOXIA&reg; can increase<br />blood pressure in some people, especially in high doses, and your doctor will want to check your blood pressure from time to time.<br />&bull; You have any history of liver or kidney disease.<br />&bull; You are being treated for an infection. ATOXIA&reg; can mask or hide a fever, which is a sign of infection.<br />&bull; You have diabetes, high cholesterol, or are a smoker. These can increase your risk of heart disease.<br />&bull; You are a woman trying to become pregnant.<br />&bull; You are over 65 years of age.<br />If you are not sure if any of the above apply to you, talk to your doctor before taking ATOXIA&reg; to see if this medicine is suitable<br />for you.<br />ATOXIA&reg; works equally well in older and younger adult patients.<br />If you are over 65 years of age, your doctor will want to appropriately keep a check on you. No dosage adjustment is necessary for patients over 65 years of age.<br />Children and adolescents<br />Do not give this medicine to children and adolescents under 16 years of age.<br /><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.<br />In particular if you are taking any of the following medicines, your doctor may want to monitor you to check that your medicines are working properly, once you start taking ATOXIA&reg;:<br />- Medicines that thin your blood (anticoagulants), such as warfarin<br />- Rifampicin (an antibiotic)<br />- Methotrexate (a drug used for suppressing the immune system, and often used in rheumatoid arthritis)<br />- Ciclosporin or tacrolimus (drugs used for suppressing the immune<br />system)<br />- Lithium (a medicine used to treat some types of depression)<br />- Medicines used to help control high blood pressure and heart failure called ACE inhibitors and angiotensin receptor blockers, examples include enalapril and ramipril, and losartan and valsartan<br />- Diuretics (water tablets)<br />- Digoxin (a medicine for heart failure and irregular heart rhythm)<br />- Minoxidil (a drug used to treat high blood pressure)<br />- Salbutamol tablets or oral solution (a medicine for asthma)<br />- Birth control pills (the combination may increase your risk of side effects)<br />- Hormone replacement therapy (the combination may increase your risk of side effects)<br />- Aspirin, the risk of stomach ulcers is greater if you take ATOXIA<br />&reg; with aspirin.</p><p>Aspirin for prevention of heart attacks or stroke:<br />ATOXIA&reg; can be taken with low-dose aspirin. If you are currently<br />taking low-dose aspirin to prevent heart attacks or stroke, you should not stop taking aspirin until you talk to your doctor<br />Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs):<br />Do not take high dose aspirin or other anti-inflammatory medicines<br />while taking ATOXIA&reg;.<br /><strong>d. Taking ATOXIA&reg; with food and drink</strong><br />The onset of the effect of ATOXIA&reg; may be faster when taken without food.</p><p><strong>e. Pregnancy and breast-feeding</strong><br />Pregnancy<br />ATOXIA&reg; tablets must not be taken during pregnancy. If you are pregnant or think you could be pregnant, or if you are planning<br />to become pregnant, do not take the tablets. If you become pregnant, stop taking the tablets and consult your doctor. Consult your doctor if you are unsure or need more advice.<br />Breast-feeding<br />It is not known if ATOXIA&reg; is excreted in human milk. If you are breast-feeding, or planning to breast-feed, consult your doctor before taking ATOXIA&reg;. If you are using ATOXIA&reg;, you must not breast-feed.<br />f. Driving and using machines<br />Dizziness and sleepiness have been reported in some patients taking ATOXIA&reg;. Do not drive if you experience dizziness or sleepiness. Do not use any tools or machines if you experience dizziness or sleepiness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Do not take more than the recommended dose for your condition. Your doctor will want to discuss your treatment from time to time. It is important that you use the lowest dose that controls your pain and you should not take ATOXIA&reg; for longer than necessary.<br />This is because the risk of heart attacks and strokes might increase after prolonged treatment, especially with high doses.<br />There are different strengths available for this medicinal product and depending on your disease your doctor will prescribe the tablet strength that is appropriate for you.<br />The recommended dose is:<br />Osteoarthritis<br />The recommended dose is 30 mg once a day, increase to a maximum<br />of 60 mg once a day if needed.<br />Rheumatoid arthritis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day if needed.<br />Ankylosing spondylitis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day if needed.<br />Acute pain conditions<br />Etoricoxib should be used only for the acute painful period.<br />Gout<br />The recommended dose is 120 mg once a day which should only be used for the acute painful period, limited to a maximum of 8 days treatment.<br />Postoperative dental surgery pain<br />The recommended dose is 90 mg once daily, limited to a maximum<br />of 3 days treatment.<br />People with liver problems<br />&bull; If you have mild liver disease, you should not take more than 60 mg a day.<br />&bull; If you have moderate liver disease, you should not take more than 30 mg a day.<br />Use in children and adolescents<br />ATOXIA&reg; tablets should not be taken by children or adolescents<br />under 16 years of age.<br />Elderly<br />No dose adjustment is necessary for elderly patients. As with other medicines, caution should be exercised in elderly patients.<br />Method of administration<br />ATOXIA&reg; is for oral use. Take the tablets once a day. ATOXIA<br />&reg; can be taken with or without food.<br /><strong>a. If you take more ATOXIA&reg; than you should</strong><br />You should never take more tablets than the doctor recommends.<br />If you do take too many<br />ATOXIA&reg; tablets, you should seek medical attention immediately.</p><p><strong>b. If you forget to take ATOXIA&reg;</strong><br />It is important to take ATOXIA&reg; as your doctor has prescribed. If you miss a dose, just resume your usual schedule the following<br />day. Do not take a double dose to make up for the forgotten tablet.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you develop any of these signs you should stop ATOXIA&reg; and talk to your doctor immediately:<br />- Shortness of breath, chest pains, or ankle swelling appear or if they get worse<br />- Yellowing of the skin and eyes (jaundice) &ndash; these are signs of liver problems<br />- Severe or continual stomach pain or your stools become black<br />- An allergic reaction- which can include skin problems such as ulcers or blistering, or swelling of the face, lips, tongue, or throat which may cause difficulty in breathing<br />The frequency of possible side effects listed below is defined using<br />the following convention:<br />Very common (affects more than 1 user in 10)<br />Common (affects 1 to 10 users in 100)<br />Uncommon (affects 1 to 10 users in 1,000)<br />Rare (affects 1 to 10 users in 10,000)<br />Very rare (affects less than 1 user in 10,000)<br />The following side effects can occur during treatment with ATOXIA&reg;:<br />Very Common<br />&bull; Stomach pain<br />Common<br />&bull; Dry socket (inflammation and pain after a tooth extraction)<br />&bull; swelling of the legs and/or feet due to fluid retention (oedema)<br />&bull; Dizziness, headache<br />&bull; Palpitations (fast or irregular heartbeat), irregular heart rhythm (arrhythmia)<br />&bull; increased blood pressure<br />&bull; Wheezing or shortness of breath (bronchospasms)<br />&bull; Constipation, wind (excessive gas), gastritis (inflammation of the lining of the stomach), heartburn, diarrhoea, indigestion (dyspepsia)/stomach discomfort, nausea, being sick (vomiting), inflammation of the oesophagus, mouth ulcers<br />&bull; Changes in blood tests related to your liver<br />&bull; Bruising<br />&bull; Weakness and fatigue, flu-like illness<br />Uncommon<br />&bull; Gastroenteritis (inflammation of the gastrointestinal tract that involves both the stomach and small intestine/stomach flu), upper<br />respiratory infection, urinary tract infection<br />&bull; Changes in laboratory values (decreased number of red blood cells, decreased number of white blood cells, platelets decreased)<br />&bull; Hypersensitivity (an allergic reaction including hives which may be serious enough to require immediate medical attention)<br />&bull; Appetite increases or decreases, weight gain<br />&bull; Anxiety, depression, decreases in mental sharpness; seeing, feeling or hearing things that are not there (hallucinations)<br />&bull; Taste alteration, inability to sleep, numbness or tingling, sleepiness<br />&bull; Blurred vision, eye irritation and redness<br />&bull; Ringing in the ears, vertigo (sensation of spinning while remaining<br />still)<br />&bull; Abnormal heart rhythm (atrial fibrillation), fast heart rate, heart failure, feeling of tightness, pressure or heaviness in the chest (angina pectoris), heart attack<br />&bull; Flushing, stroke, mini-stroke (transient ischaemic attack), severe<br />increase in blood pressure. Inflammation of the blood vessels<br />&bull; Cough, breathlessness, nose bleed<br />&bull; Stomach or bowel bloating, changes in your bowel habits, dry&nbsp;mouth, stomach ulcer, inflammation of the stomach lining that can become serious and may lead to bleeding, irritable bowel syndrome, inflammation of the pancreas<br />&bull; Swelling of the face, skin rash or itchy skin, redness of the skin<br />&bull; Muscle cramp/spasm, muscle pain/stiffness<br />&bull; High levels of potassium in your blood, changes in blood or urine tests relating to your kidney, serious kidney problems<br />&bull; Chest pain<br /><strong>Rare</strong><br />&bull; Angioedema (an allergic reaction with swelling of the face, lips, tongue and/or throat which may cause difficulty in breathing or swallowing, which may be serious enough to require immediate medical attention)/anaphylactic/anaphylactoid reactions including<br />shock (a serious allergic reaction that requires immediate medical attention)<br />&bull; Confusion, restlessness<br />&bull; Liver problems (hepatitis)<br />&bull; Low blood levels of sodium<br />&bull; Liver failure, yellowing of the skin and/or eyes (jaundice)<br />&bull; Severe skin reactions</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.<br />- Don&rsquo;t store above 30&deg;C<br />- Do not use ATOXIA&reg; after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />- Medicines should not be disposed of via wastewater or household<br />waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is: Etoricoxib.<br />ATOXIA&reg; 90: Each film coated tablet contains 90mg Etoricoxib.<br />&bull; The other ingredients are for:</p><p>ATOXIA&reg; 90: Calcium hydrogen phosphate anhydrous, Microcrystalline<br />Cellulose, Croscarmellose Sodium, Colloidal Silicon Dioxide, Magnesium Stearate, Opadry white Y-1-7000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                - Film coated tablet
- Physical Description:
ATOXIA® 90: White, apple shaped biconvex film coated tablets embossed with T47.
- ATOXIA® is packed in blisters of Aluminum / Aluminum foil blister, in carton box with a folded leaflet.
- Pack sizes:
ATOXIA® 90: is available in the pack size of 10 F.C. tablets (10 tablets/blister/pack).
Hospital packs are also available.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma-Saudi<br />King Abdulaziz road - Alrabea District<br />Grand Center 1st floor &ndash; Front of Kingdom Hospital<br />P.O Box 47315 Riyadh, 13456 Saudi Arabia<br />Phone: + 966112790122 Ext. 200<br />Fax: +966112471323<br />E-mail: Albaraa.bahhari@mspharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April, 2016; version number
M3-14-1047

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">الدوائية</p><p style="direction: rtl;">يحتوي اتوكسيا على المادة الفعالة إيتوريكوكسب. اتوكسيا هو واحد من مجموعة الادوية التي تسمى مثبطات إنزيم كوكس2 الانتقائية. هذه تنتمي الى عائلة الادوية التي تسمى مضادات الالتهاب اللاستيرويدية</p><p style="direction: rtl;">- الاستعمالات العلاجية</p><p style="direction: rtl;">يساعد اتوكسيا على الحد من الألم والتورم (الالتهاب)&nbsp;في المفاصل والعضلات لدى الأشخاص الذين يبلغون&nbsp; 16 سنة وأكبر والذين يعانون من فصال عظمي (التهاب المفاصل العظمي)، التهاب المفاصل الروماتيزمي، التهاب الفَقار المُقَسِّط والنقرس&nbsp;</p><p style="direction: rtl;">&nbsp;يستعمل اتوكسيا ايضا كعلاج قصير الأمد للألم المتوسط والذي يعقب جراحة الأسنان.في المرضى الذين يبلغون 16 سنة من العمر وأكبر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">أ. لا تأخذ اتوكسيا</p><p style="direction: rtl;">&bull; إذا كنت تعاني من حساسية (فرط الحساسية) لمادة إيتوريكوكسب أو لأي من السواغات الأخرى</p><p style="direction: rtl;">&nbsp;&bull; إذا كان لديك حساسية من الأدوية المضادة للالتهاب اللاستيرويدية (المسكنات)، بما في ذلك الاسبرين ()ومثبطات انزيم كوكس 2.</p><p style="direction: rtl;">&bull; إذا كان لديك حاليا قرحة المعدة أوتعاني من نزيف في المعدة أو الأمعاء.</p><p style="direction: rtl;">&bull; إذا كان لديك مرض في الكبد شديد.</p><p style="direction: rtl;">&bull; إذا كان لديك مرض في الكلى شديد.</p><p style="direction: rtl;">&bull; إذا كنتِ حاملا أو تعتقدين بأنك قد تكونين حاملا أو كنت ترضعين رضاعة طبيعية.</p><p style="direction: rtl;">&bull; إذا كنت تحت عمر 16 سنة.</p><p style="direction: rtl;">&bull; إذا كنت تعاني من مرض التهاب الامعاء، مثل مرض كراون، التهاب القولون التقرحي، أو التهاب القولون.</p><p style="direction: rtl;">&bull; إذا كنت مصابا بارتفاع ضغط الدم الذي لم يسيطر عليه بالعلاج عليك مراجعة الطبيب أو الممرض إذا كنت غير واثق من السيطرة على ضغط الدم بشكل كاف.</p><p style="direction: rtl;">&bull; إذا كان قد تم تشخيصك من قبل الطبيب بأن لديك مشاكل في القلب بما في ذلك فشل القلب أنواع معتدلة أو&nbsp; شديدة من الفشل القلبي، الذبحة الصدرية -ألم في الصدر.&nbsp;</p><p style="direction: rtl;">&bull; إذا كنت قد تعرضت لنوبة قلبية، أو جراحة الشرايين التحويلية، أو أمراض الشرايين الطرفية (ضعف الدورة الدموية في الساقين أو القدمين بسبب ضيق أو انسداد الشرايين.(</p><p style="direction: rtl;">&bull; إذا كنت قد تعرضت لأي نوع من السكتة الدماغية (بما في ذلك السكتة الدماغية المصغرة، أو السكتة الدماغية&nbsp; العابرة). قد يزيد أيتيروكوكسيب قليلا من خطر الاصابة بالنوبات القلبية والسكتة الدماغية، ولهذا السبب يجب عدم استعماله في أولئك الذين لديهم بالفعل مشاكل في القلب أو تعرضوا لسكتة دماغية. إذا كنت تعتقد أن أي من هذه الأمور له صلة بك، لا تتناول الأقراص حتى تتمكن من استشارة الطبيب</p><p style="direction: rtl;"><strong>ب. الاحتياطات عند استعمال اتوكسيا</strong></p><p style="direction: rtl;"><strong>تحدث مع طبيبك أو الصيدلاني قبل أخذ اتوكسيا</strong></p><p style="direction: rtl;">&bull; لديك تاريخ مسبق للإصابة بنزيف في المعدة أو القرحة.</p><p style="direction: rtl;">&bull; كنت مصابا بالجفاف، على سبيل المثال، بعد أن تكون قد تعرضت لنوبة طويلة من التقيؤ أو الإسهال.</p><p style="direction: rtl;">&bull; أصبت بتورم بسبب احتباس السوائل.</p><p style="direction: rtl;">&bull; لديك تاريخ مسبق من فشل القلب والسكتة القلبية، أو أي شكل آخر من أشكال أمراض القلب.</p><p style="direction: rtl;">&bull; لديك تاريخ مسبق من ارتفاع ضغط الدم. قد يؤدي اتوكسيا إلى زيادة ضغط الدم لدى بعض الناس، وخاصة عند تناول الجرعات العالية، وسيقوم الطبيب بمتابعة ضغط الدم لديك من وقت لآخر.</p><p style="direction: rtl;">&bull; لديك أي تاريخ مسبق لأمراض الكبد أو أمراض الكلى.</p><p style="direction: rtl;">&bull; تمت معالجتك لإصابتك بعدوى. قد يخفي اتوكسيا أو يحجب الحمى، والتي تعتبر علامة للإصابة بالعدوى.</p><p style="direction: rtl;">&bull; كان لديك مرض السكري، ارتفاع الكوليسترول في الدم، أو كنت مدخنا. يمكن لهذه الأمور أن تزيد من مخاطر الإصابة بأمراض القلب.</p><p style="direction: rtl;">&bull; كنت سيدة وتحاولين ان تصبحي حاملا.</p><p style="direction: rtl;">&bull; كان عمرك أي أكثر من 65 سنة من العمر.</p><p style="direction: rtl;">لم تكن متأكدا مما إذا كان أي مما ورد أعلاه ينطبق عليك، فتحدث إلى طبيبك قبل تناول اتوكسيا لمعرفة ما إذا كان هذا الدواء مناسب لك أم لا.</p><p style="direction: rtl;">يعمل اتوكسيا بشكل جيد ومماثل في المرضى البالغين والمسنين. إذا كان عمرك أكثر من 65 سنة من العمر، فسيقوم طبيبك وعلى نحو مناسب بمتابعتك. ليس من الضروري تعديل الجرعة للمرضى الاكبر من 65 سنة.الاطفال والمراهقينلا تعطي هذا الدواء للاطفال والمراهقين الاصغر من 16 سنة من العمر.</p><p style="direction: rtl;">يرجى إخبار الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت في الآونة الأخيرة أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p style="direction: rtl;">لا سيما إذا كنت تتناول أي من الأدوية التالية، فقد يحتاج طبيبك لمتابعتك للتأكد من أن الأدوية الخاصة بك تعمل بشكل صحيح، وذلك بمجرد البدء في تناول اتوكسيا :</p><p style="direction: rtl;">&bull; الأدوية التي تميع الدم (مضادات التخثر) مثل الوارفارين.</p><p style="direction: rtl;">&bull; ريفامبيسين- مضاد حيوي .</p><p style="direction: rtl;">&bull; ميثوتريكسيت- هو دواء يستعمل لتثبيط نظام المناعة، وغالبا ما يستعمل في التهاب المفاصل الروماتيزمي.</p><p style="direction: rtl;">&bull; سيكلوسبورين أو تاكروليماس - الأدوية المستعملة لتثبيط نظام المناعة .</p><p style="direction: rtl;">&bull; الليثيوم - هو دواء يستعمل لعلاج بعض أنواع الاكتئاب.</p><p style="direction: rtl;">&bull; الأدوية المستعملة للمساعدة في السيطرة على ضغط الدم المرتفع وقصور القلب وتسمى مثبطات الانزيم المحول للانجيوتنسنجين وحاصرات مستقبلات الأنجيوتنسين، ومن الأمثلة على ذلك إنالابريل وراميبريل ولوسارتان و فالسارتان.</p><p style="direction: rtl;">&bull; مدرات البول - أقراص الماء .</p><p style="direction: rtl;">&bull; ديجوكسين - دواء لقصور القلب وعدم انتظام ضربات القلب .</p><p style="direction: rtl;">&bull; مينوكسيديل - هو دواء يستعمل لعلاج ارتفاع ضغط الدم .</p><p style="direction: rtl;">&bull; أقراص سالبوتامول أو المحلول الفموي -&nbsp;دواء لعلاج الربو .</p><p style="direction: rtl;">&bull; حبوب تنظيم الحمل- العلاج المترافق قد يزيد من احتمالية حدوث الاثار الجانبية.</p><p style="direction: rtl;">&bull; العلاج بالهرمونات البديلة -&nbsp;العلاج المترافق قد يزيد من احتمالية حدوث الاثار الجانبية.</p><p style="direction: rtl;">&bull; الأسبرين، إن خطر قرحة المعدة يزيد عند تناول اتوكسيا مع الأسبرين الاسبرين لمنع حدوث النوبات القلبية أو السكتة الدماغية:</p><p style="direction: rtl;">يمكن تناول اتوكسيا مع جرعة منخفضة من الاسبرين . إذا كنت تتناول حاليا جرعة منخفضة من الاسبرين لمنع النوبات القلبية او السكتة الدماغية، فيجب عدم التوقف عن تناول الاسبرين حتى تتحدث مع طبيبكلا تتناول جرعة عالية من الأسبرين أو غيره من الأدوية المضادة للالتهابات أثناء تناولك اتوكسيا .</p><p style="direction: rtl;"><strong>د. تناول اتوكسيا مع الطعام والشراب</strong></p><p style="direction: rtl;">ان بداية تأثير اتوكسيا قد تكون اسرع عند أخذ اتوكسيا بدون تناول الطعام.</p><p style="direction: rtl;"><strong>هـ. الحمل والرضاعة الحمل</strong></p><p style="direction: rtl;">يجب عدم تناول أقراص اتوكسيا خلال فترة الحمل. إذا كنت حاملا أو تعتقدين بأنك قد تكونين حاملا، أو إذا كنت تخططين لتصبحي حاملا، فلا تتناولي هذه الأقراص. إذا أصبحت حاملا، توقفي عن تناول الأقراص واستشيري الطبيب . استشيري طبيبك إذا كنت غير متأكدة أو بحاجة الى مزيد من المشورة.</p><p style="direction: rtl;"><strong>الرضاعة</strong>:</p><p style="direction: rtl;">ليس معروفا ما إذا كان اتوكسيا يفرز في حليب الأم المرضعة . إذا كنت ترضعين رضاعة طبيعية، أو تخطيطن للرضاعة الطبيعية، فعليك استشارة الطبيب قبل تناول اتوكسيا . إذا كنت تتناولين اتوكسيا ، فيجب عدم ارضاع طفلك طبيعيا.</p><p style="direction: rtl;"><strong>و. القيادة واستعمال الآلات </strong></p><p style="direction: rtl;">تم الإبلاغ عن حدوث دوخة ونعاس في بعض المرضى الذين يتناولون إيتوريكوكسب. لا تقم بالقيادة إذا شعرت بالدوخة أو النعاس. لا تستعمل أي أدوات أو آلات إذا شعرت بالدوخة أو النعاس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">&nbsp;</p><p style="direction: rtl;">دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلاني. استشر طبيبك أو الصيدلاني إذا لم تكن متأكدا. لا تتناول أكثر من الجرعة الموصى بها لحالتك. سيقوم طبيبك بمناقشة العلاج الخاص بك من وقت لآخر . من المهم أن تستعمل أقل جرعة ممكنة للتحكم بالألم، ويجب عدم تناول اتوكسيا لفترة أطول من اللازم. هذا لأن خطر النوبات القلبية والسكتات الدماغية قد يزيد بعد تناول العلاج لفترات طويلة، خاصة مع الجرعات الكبيرة.هناك تراكيز مختلفة المتاحة لهذا المنتج الطبي واعتمادا على مرضك سيصف لك الطبيب التركيز المناسب لك</p><p style="direction: rtl;"><strong>تبلغ الجرعة الموصى بها</strong><strong>: </strong></p><p style="direction: rtl;"><strong>فصال عظمي (التهاب المفاصل العظمي)</strong><strong>: </strong>&nbsp;تبلغ الجرعة الموصى بها 30 ملغم مرة واحدة يوميا، ويمكن زيادتها بحد أقصى إلى 60 ملغم مرة واحدة يوميا إذا لزم الأمر.</p><p style="direction: rtl;"><strong>التهاب المفاصل الروماتيزمي</strong><strong>:</strong> تبلغ الجرعة الموصى بها 60 ملغم مرة واحدة في اليوم. ويمكن زيادتها بحد أقصى إلى 90 ملغم مرة واحدة يوميا إذا لزم الأمر.</p><p style="direction: rtl;"><strong>التهاب الفَقار المُقَسِّط</strong><strong>:</strong> تبلغ الجرعة الموصى بها 60 ملغم مرة واحدة في اليوم. ويمكن زيادتها بحد أقصى إلى 90 ملغم مرة واحدة يوميا إذا لزم الأمر.</p><p style="direction: rtl;">يجب اقتصار استعمال إيتوريكوكسب في فترة الألم الحاد.</p><p style="direction: rtl;"><strong>النقرس</strong><strong>:</strong> تبلغ الجرعة الموصى بها 120 ملغم مرة واحدة في اليوم ويجب استعماله فقط لفترة الألم الحاد، ويقتصر الحد الأقصى للعلاج على 8 أيام.</p><p style="direction: rtl;"><strong>ألم ما بعد عمليات جراحة الأسنان</strong><strong>:</strong> تبلغ الجرعة الموصى بها 90 ملغم مرة واحدة في اليوم، ويقتصر الحد الأقصى للعلاج على 3 أيام.</p><p style="direction: rtl;"><strong>الأشخاص الذين يعانون من مشاكل في الكبد</strong></p><p style="direction: rtl;">&bull; إذا كنت تعاني من مرض كبدي بسيط، يجب عدم تناول أكثر من 60 ملغم يوميا.</p><p style="direction: rtl;">&bull; إذا كنت تعاني من مرض كبدي معتدل، يجب عدم تناول أكثر من 30 ملغم يوميا.</p><p style="direction: rtl;"><strong>الاستعمال في الاطفال والمراهقين</strong><strong>:</strong> يجب عدم اعطاء أقراص اتوكسيا للاطفال والمراهقين الاصغر من 16 سنة من العمر.</p><p style="direction: rtl;"><strong>المسنين</strong><strong>:</strong> من غير الضروري تعديل الجرعة في المرضى المسنين. كما هو الحال مع باقي الادوية، يجب أخذ الحيطة والحذر في المرضى المسنين.</p><p style="direction: rtl;"><strong>طريقة الاعطاء</strong><strong>:</strong> إن اتوكسيا هي للاستعمال عن طريق الفم. تناول الأقراص مرة واحدة يوميا. يمكن تناول اتوكسيا مع أو بدون الطعام.</p><p style="direction: rtl;"><strong>أ. إذا تناولت اتوكسيا أكثر مما يجب</strong><strong> :&nbsp;</strong>يجب عدم تناول أكثر من الجرعة الموصى بها . إذا تناولت الكثير من أقراص اتوكسيا ، فعليك طلب العناية الطبية على الفور.</p><p style="direction: rtl;"><strong>ب. إذا نسيت تناول اتوكسيا</strong><strong>:</strong> من المهم تناول اتوكسيا كما وصفه لك الطبيب. إذا كنت قد نسيت تناول الجرعة، فعليك فقط استئناف الجدول الزمني الخاص بك كالمعتاد في اليوم التالي. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.إذا كان لديك أي أسئلة أخرى عن استعمال هذا المنتج، اسأل طبيبك أو الصيدلاني.</p><p style="direction: rtl;"><strong>ج. إذا توقفت عن تناول اتوكسيا</strong><strong> :&nbsp;</strong>من المهم أن تأخذ اتوكسيا كما وصف طبيبك ذلك. إذا نسيت تناول جرعة، فقط قم باستئناف العلاج الخاص بك كالمعتاد في اليوم التالي. لا تأخذ جرعة مضاعفة لتعويض القرص المنسي.إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p style="direction: rtl;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p style="direction: rtl;">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، وعلى الرغم من أن الجميع لا يصاب بها.</p><p style="direction: rtl;">إ<strong>ذا أصبت بأي من هذه العلامات فيجب أن تتوقف عن تناول اتوكسيا وعليك التحدث الى الطبيب فورا</strong><strong>:</strong> &bull; ضيق في التنفس، آلام في الصدر، أو ظهور تورم في الكاحل أو عند ازدياد الحالة سوءا. &bull; اصفرار الجلد والعينين (اليرقان) - وهذه هي علامات حدوث مشاكل في الكبد &bull; آلام حادة أو مستمرة في المعدة أو البراز يصبح أسود اللون &bull; ردود فعل تحسسي والذي يمكن أن يتضمن مشاكل في الجلد مثل تقرحات أو بثور، أو تورم في الوجه والشفتين واللسان، أو الحلق مما قد يسبب صعوبة في التنفس.</p><p style="direction: rtl;">يتم تعريف تردد حدوث الاثار الجانبية المحتملة الواردة أدناه باستخدام الاصطلاحات التالية:</p><p>(شائعة جدا (يؤثر على أكثر من شخص في كل 10 أشخاص<br />(شائعة (يؤثر في 1-10 اشخاص في كل 100 شخص<br />(غير شائع (يؤثر في 1-10 اشخاص في كل 1000 شخص<br />(نادرة (يؤثر في 1-10 اشخاص في كل 10000 شخص<br />(نادرة جدا (يؤثر على أقل من شخص في كل شخص10000</p><p style="direction: rtl;">يمكن أن تحدث الآثار الجانبية التالية أثناء العلاج مع اتوكسيا :</p><p style="direction: rtl;"><strong>شائعة جدا</strong><strong>:</strong></p><p style="direction: rtl;">&bull; الم في المعدة.</p><p style="direction: rtl;"><strong>شائعة</strong><strong>: </strong></p><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; السنخ الجاف - التهاب وألم بعد قلع الأسنان</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; تورم في الساقين و / أو القدمين بسبب احتباس السوائل - وذمة</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; الدوخة والصداع</span></div><p style="direction: rtl;">&bull; الخفقان (سرعة ضربات القلب أو عدم انتظامها)، عدم انتظام ضربات القلب عدم&nbsp;</p><p style="direction: rtl;">&bull; ارتفاع ضغط الدم</p><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; صفير أو ضيق في التنفس - تشنج الشعب الهوائية</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; الإمساك، والنفخة (غاز مفرط)، التهاب المعدة (التهاب بطانة المعدة)، حرقة والإسهال وسوء الهضم (عسر الهضم) / المغص والغثيان، والشعور بالمرض -القيء، والتهاب في المريء، وقرحة الفم</span></div><p style="direction: rtl;">&bull; تغيرات في فحوصات الدم المتعلقة بالكبد</p><p style="direction: rtl;">&bull; كدمات</p><p style="direction: rtl;">&bull; ضعف وتعب مرض يشبه الانفلونزا</p><p style="direction: rtl;"><strong>غير شائعة</strong><strong>:</strong></p><p style="direction: rtl;">&bull; التهاب المعدة والأمعاء (التهاب الجهاز الهضمي الذي يشمل كلا من المعدة والأمعاء الدقيقة / انفلونزا المعدة)، التهاب الجهاز التنفسي العلوي، التهاب المسالك البولية</p><p style="direction: rtl;">&bull; التغيرات في القيم المخبرية - انخفاض عدد خلايا الدم الحمراء، وانخفاض عدد خلايا الدم البيضاء، وانخفاض الصفائح الدموية&nbsp;</p><p style="direction: rtl;">&bull; فرط الحساسية - تفاعلات الحساسية بما في ذلك الشرى التي قد تكون خطيرة بما يكفي لتتطلب عناية طبية فورية</p><p style="direction: rtl;">&bull; زيادة الشهية أو نقصانها، زيادة الوزن</p><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; القلق، والاكتئاب، انخفاض الحدة العقلية؛ انخفاض رؤية، الشعور أو سماع أشياء غير موجودة - الهلوسة</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; تغير الطعم ، وعدم القدرة على النوم، وخدر أو وخز، والنعاس</span></div><p style="direction: rtl;">&bull; عدم وضوح الرؤية، وتهيج العين واحمرارها</p><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; طنين في الآذان، والدوار -&nbsp;الشعور بالدوار وانت واقف</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; إيقاع غير طبيعي للقلب&nbsp;(الرجفان الأذيني)، سرعة دقات القلب، وفشل القلب، والشعور بالضيق، وضغط أو ()ثقل في الصدر (الذبحة الصدرية)، بنوبة قلبية</span></div><p style="direction: rtl;">&bull; توهج ، والسكتة الدماغية، جلطة دماغية بسيطة (نوبة نقص تروية عابرة)، وزيادة حادة في ضغط الدم.التهاب الأوعية الدموية</p><p style="direction: rtl;">&bull; السعال، ضيق التنفس، نزف الأنف</p><p style="direction: rtl;">&bull; نفخة في المعدة أو الأمعاء، التغيرات في عادة الأمعاء، وجفاف الفم، قرحة المعدة، التهاب بطانة المعدة يمكن أن تصبح خطيرة وربما يؤدي إلى حدوث النزيف، ومتلازمة القولون العصبي، والتهاب البنكرياس</p><p style="direction: rtl;">&bull; تورم في الوجه، طفح جلدي أو حكة في الجلد، واحمرار في الجلد&bull; تشنج العضلات / تشنج وآلام في العضلات / صلابة</p><p style="direction: rtl;">&bull; مستويات عالية من البوتاسيوم في الدم، والتغيرات في اختبارات الدم أو البول المتعلقة بالكلى، مشاكل خطيرة في الكلى</p><p style="direction: rtl;">&bull; ألم في الصدر</p><p style="direction: rtl;"><strong>نادر</strong><strong>:</strong></p><p style="direction: rtl;">&bull; وذمة وعائية (ردود فعل تحسسية مع تورم في الوجه والشفتين واللسان و / أو الحلق مما قد يسبب صعوبة&nbsp; في التنفس أو البلع، والتي قد تكون خطيرة بما يكفي لتتطلب عناية طبية فورية )/ ردود الفعل تأقانية / الحساسية بما فيها صدمة (ردود فعل حساسية خطيرة والتي تتطلب عناية طبية فورية)ء</p><p style="direction: rtl;">&bull; الارتباك، والأرق</p><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; مشاكل الكبد -&nbsp;التهاب الكبد</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; مستويات منخفضة من الصوديوم</span></div><p>&nbsp;</p><div style="direction: rtl;"><span style="text-align:unset">&bull; فشل الكبد، اصفرار الجلد و / أو العينين - اليرقان</span></div><div style="direction: rtl;"><span style="text-align:unset">&bull; ردود فعل شديدة في الجلد</span></div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p style="direction: rtl;">يحفظ بعيدا عن متناول وبصر الأطفال.</p><p style="direction: rtl;">&nbsp;يحفظ في درجة حرارة لا تتجاوز 30&deg; م.</p><p style="direction: rtl;">لا تستعمل اتوكسيا بعد تاريخ انتهاء الصلاحية التي توضع على العلبة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p style="direction: rtl;">يجب عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">أ. ما هي محتويات اتوكسيا</p><p style="direction: rtl;">- المادة الفعالة هي: إيتوريكوكسب.</p><p style="direction: rtl;">&nbsp;اتوكسيا 90: كل قرص مغلف يحتوي على 90ملغم إيتوريكوكسب .</p><p style="direction: rtl;">&nbsp;المكونات الأخرى هي :</p><p style="direction: rtl;">اتوكسيا 90: فوسفات هيدروجين الكالسيوم لامائي، ميكروكريستالاين السيلليلوز, كروسكارميللوز صوديوم, ثنائي أوكسيد السيليكون الغروي ، ماغنيسيوم ستيريت, أوبادراي أبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            
- أقراص مغلفة .
 - الوصف الخارجي:
اتوكسيا 90: أقراص بيضاء مغلفة على شكل التفاح محدبة الوجهين منقوشة ب T47
- يعبأ اتوكسيا في أشرطة المونيوم / المونيوم، موضوعة في عبوات كرتونية مع نشرات طبية مطوية.
 - حجم العبوة:  
اتوكسيا  90: يتوفر في عبوات سعة 10 أقراص مغلفة (10 أقراص / شريط / عبوة).
- عبوات المستشفيات متوفرة أيضاً.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">إم إس فارما- السعودية</p><p style="direction: rtl;">طريق الملك عبدالعزيز - حي الربيع</p><p style="direction: rtl;">مبنى جراند سنتر الطابق الأول-مقابل مستشفى المملكة</p><p style="direction: rtl;">ص.ب. 47315 الرياض، 13456 السعودية</p><p style="direction: rtl;">&nbsp;هاتف: 966112790122 + فرعي:200</p><p style="direction: rtl;">فاكس: 966112471323+</p><p style="direction: rtl;">البريد الالكتروني:</p><p style="direction: rtl;">Albaraa.bahhari@mspharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            April, 2016؛ رقم النسخة : 1047-14-M3
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ATOXIA® 90mg Film Coated Tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amount (mg)/one tablet 	Function 	Material Name 
90.0	Active Material 	Etoricoxib 
75.0	Diluent	Calcium hydrogen phosphate anhydrous
279.0	Diluent	Microcrystalline Cellulose
9.3	Disintegrant	Crosscarmellose sodium
4.7	Glidant	Colloidal Silicon Dioxide
7.0	Lubricant 	Magnesium Stearate 
465.0	Total weight before coating 
14.1	Coating agent	Opadry White Y-1-7000

For a full list of excipients, see section 6.1 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets
Atoxia 90mg F/C Tablets Description: White, apple shaped biconvex film coated tablets embossed with T47.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATOXIA<sup>&reg; </sup></strong>is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis.</p><p><strong>ATOXIA<sup>&reg; </sup></strong>is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery.</p><p>The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient&#39;s overall risks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Orally.</p><p>Posology</p><p>As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><p><strong><em>Osteoarthritis</em></strong></p><p>The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p><strong><em>Rheumatoid arthritis</em></strong></p><p>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p><strong><em>Ankylosing spondylitis</em></strong></p><p>The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p><strong><em>Acute pain conditions </em></strong></p><p>For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.</p><p><strong><em>Acute gouty arthritis</em></strong></p><p>The recommended dose is 120 mg once daily. For acute gouty arthritis, etoricoxib was given for 8 days.</p><p><strong><em>Postoperative dental surgery pain</em></strong></p><p>The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to <strong>ATOXIA<sup>&reg; </sup></strong>during the three day treatment period.</p><p>Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore:</p><p>The dose for OA should not exceed 60 mg daily.</p><p>The dose for RA and ankylosing spondylitis should not exceed 90 mg daily.</p><p>The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment.</p><p>The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days.</p><p><strong><u>Special populations</u></strong></p><p><strong><em>Elderly patients</em></strong></p><p>No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients.</p><p><strong><em>Patients with hepatic impairment</em></strong></p><p>Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh scores 5-6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 30 mg&nbsp;<em>once daily&nbsp;</em>should not be exceeded.</p><p>Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score &ge;10); therefore, its use is contra-indicated in these patients.</p><p><strong><em>Patients with renal impairment</em></strong></p><p>No dosage adjustment is necessary for patients with creatinine clearance &ge;30 ml/min. The use of etoricoxib in patients with creatinine clearance &lt;30 ml/min is contra-indicated.</p><p><strong><em>Paediatric population</em></strong></p><p>Etoricoxib is contra-indicated in children and adolescents under 16 years of age.</p><p><strong>Method of administration</strong></p><p><strong>ATOXIA<sup>&reg; </sup></strong>is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when <strong>ATOXIA<sup>&reg; </sup></strong>is administered without food. This should be considered when rapid symptomatic relief is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients. 
•	Active peptic ulceration or active gastro-intestinal (GI) bleeding.
•	Patients who, after taking acetylsalicylic or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions.
•	Pregnancy and lactation.
•	Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
•	Estimated renal creatinine clearance <30 ml/min.
•	Children and adolescents under 16 years of age.
•	Inflammatory bowel disease.
•	Congestive heart failure (NYHA II-IV).
•	Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled.
•	Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Gastrointestinal effects</em></strong></p><p>Upper gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with etoricoxib.</p><p>Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>There is a further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when etoricoxib is taken concomitantly with acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid&nbsp;<em>vs</em>. NSAIDs + acetylsalicylic acid has not been demonstrated.</p><p><strong><em>Cardiovascular effects</em></strong></p><p>&nbsp;The selective COX-2 inhibitor class of drugs may be associated with a risk of thrombotic events (especially myocardial infarction (MI) and stroke). As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking) should only be treated with etoricoxib after careful consideration.</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect. Therefore antiplatelet therapies should not be discontinued.</p><p><strong><em>Renal effects</em></strong></p><p>Renal prostaglandins may play a compensatory role in the maintenance of renal perfusion. Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Patients at greatest risk of this response are those with pre-existing significantly impaired renal function, uncompensated heart failure, or cirrhosis. Monitoring of renal function in such patients should be considered.</p><p><strong><em>Fluid retention, oedema and hypertension</em></strong></p><p>As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking etoricoxib. All Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including etoricoxib, can be associated with new onset or recurrent congestive heart failure. For information regarding a dose related response for etoricoxib. Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing oedema from any other reason. If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of etoricoxib should be taken.</p><p>Etoricoxib may be associated with more frequent and severe hypertension than some other NSAIDs and selective COX-2 inhibitors, particularly at high doses. Therefore, hypertension should be controlled before treatment with etoricoxib and special attention should be paid to blood pressure monitoring during treatment with etoricoxib. Blood pressure should be monitored within two weeks after initiation of treatment and periodically thereafter. If blood pressure rises significantly, alternative treatment should be considered.</p><p><strong><em>Hepatic effects</em></strong></p><p>Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients.</p><p>Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, etoricoxib should be discontinued.</p><p><strong><em>General</em></strong></p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of etoricoxib therapy should be considered. Medically appropriate supervision should be maintained when using etoricoxib in the elderly and in patients with renal, hepatic, or cardiac dysfunction.</p><p>Caution should be used when initiating treatment with etoricoxib in patients with dehydration. It is advisable to rehydrate patients prior to starting therapy with etoricoxib.</p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs and some selective COX-2 inhibitors during post-marketing surveillance. Patients appear to be at highest risk for these reactions early in the course of therapy with the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving etoricoxib. Some selective COX-2 inhibitors have been associated with an increased risk of skin reactions in patients with a history of any drug allergy. Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>Etoricoxib may mask fever and other signs of inflammation.</p><p>Caution should be exercised when co-administering etoricoxib with warfarin or other oral anticoagulants.The use of etoricoxib, as with any medicinal product known to inhibit cyclooxygenase / prostaglandin synthesis, is not recommended in women attempting to conceive<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pharmacodynamic interactions</em></strong></p><p><strong><em>Oral anticoagulants:</em></strong><em>&nbsp;</em>In subjects stabilised on chronic warfarin therapy, the administration of etoricoxib 120 mg daily was associated with an approximate 13% increase in prothrombin time International Normalised Ratio (INR). Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with etoricoxib is initiated or the dose of etoricoxib is changed.</p><p><em>Diuretics, ACE inhibitors and Angiotensin II Antagonists:&nbsp;</em>NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><strong><em>Acetylsalicylic Acid:</em></strong><em>&nbsp;</em>At steady state, etoricoxib 120 mg once daily had no effect on the anti-platelet activity of acetylsalicylic acid (81 mg once daily). Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid). However, concomitant administration of low-dose acetylsalicylic acid with etoricoxib may result in an increased rate of GI ulceration or other complications compared to use of etoricoxib alone. Concomitant administration of etoricoxib with doses of acetylsalicylic acid above those for cardiovascular prophylaxis or with other NSAIDs is not recommended.</p><p><strong><em>Ciclosporin and tacrolimus:</em></strong><em>&nbsp;</em>Although this interaction has not been studied with etoricoxib, coadministration of ciclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of ciclosporin or tacrolimus. Renal function should be monitored when etoricoxib and either of these drugs is used in combination.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Pharmacokinetic interactions</em></strong></p><p><em>The effect of etoricoxib on the pharmacokinetics of other drugs</em></p><p><em>Lithium:&nbsp;</em>NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels. If necessary, monitor blood lithium closely and adjust the lithium dosage while the combination is being taken and when the NSAID is withdrawn.</p><p><strong><em>Methotrexate:</em></strong><em>&nbsp;</em> Adequate monitoring for methotrexate-related toxicity is recommended when etoricoxib and methotrexate are administered concomitantly.</p><p><strong><em>Oral contraceptives:</em></strong><em>&nbsp;</em>Etoricoxib given concomitantly with an oral contraceptive containing ethinyl estradiol (EE) and norethindrone increased the steady state AUC0-24hr of EE This increase in EE concentration should be considered when selecting an oral contraceptive for use with etoricoxib. An increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives (e.g., venous thrombo-embolic events in women at risk).</p><p><strong><em>Hormone Replacement Therapy (HRT):</em></strong><em>&nbsp;</em> The effects of etoricoxib on the exposure (AUC0-24hr) to these estrogenic components of PREMARIN were less than half of those observed when PREMARIN was administered alone and the dose was increased. These increases in estrogenic concentration should be taken into consideration when selecting post-menopausal hormone therapy for use with etoricoxib because the increase in oestrogen exposure might increase the risk of adverse events associated with HRT.</p><p><strong><em>Prednisone/prednisolone:</em></strong><em>&nbsp;</em> etoricoxib did not have clinically important effects on the pharmacokinetics of prednisone/prednisolone.</p><p><strong><em>Digoxin:</em></strong><em>&nbsp;</em> There was an increase in digoxin Cmax This increase is not generally important for most patients. However, patients at high risk of digoxin toxicity should be monitored for this when etoricoxib and digoxin are administered concomitantly.</p><p><strong><em>Effect of etoricoxib on drugs metabolised by sulfotransferases</em></strong></p><p>Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has been shown to increase the serum concentrations of ethinyl estradiol. While knowledge about effects of multiple sulfotransferases is presently limited and the clinical consequences for many drugs are still being examined, it may be prudent to exercise care when administering etoricoxib concurrently with other drugs primarily metabolised by human sulfotransferases (e.g., oral salbutamol and minoxidil).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Effect of etoricoxib on drugs metabolised by CYP isoenzymes</em></strong></p><p>Etoricoxib is not expected to inhibit cytochromes P450 (CYP) 1A2, 2C9, 2C19, 2D6, 2E1 or 3A4. Daily administration of etoricoxib 120 mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Effects of other drugs on the pharmacokinetics of etoricoxib</em></strong></p><p>The main pathway of etoricoxib metabolism is dependent on CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib&nbsp;<em>in vivo</em>.&nbsp;<em>In vitro&nbsp;</em>studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles have not been studied&nbsp;<em>in vivo</em>.</p><p><strong><em>Ketoconazole:</em></strong><em>&nbsp;</em>Ketoconazole, a potent inhibitor of CYP3A4, dosed at 400 mg once a day for 11 days did not have any clinically important effect on the single-dose pharmacokinetics of 60 mg etoricoxib (43% increase in AUC).</p><p><em>Voriconazole and Miconazole</em>: Co-administration of either oral voriconazole or topical miconazole oral gel, strong CYP3A4 inhibitors, with etoricoxib caused a slight increase in exposure to etoricoxib, but is not considered to be clinically meaningful based on published data.</p><p><strong><em>Rifampicin:</em></strong><em>&nbsp;</em>Co-administration of etoricoxib with rifampicin, a potent inducer of CYP enzymes, produced a 65% decrease in etoricoxib plasma concentrations. This interaction may result in recurrence of symptoms when etoricoxib is co-administered with rifampicin. While this information may suggest an increase in dose, doses of etoricoxib greater than those listed for each indication have not been studied in combination with rifampicin and are therefore not recommended.</p><p><strong><em>Antacids:</em></strong><em>&nbsp;</em>Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>No clinical data on exposed pregnancies are available for etoricoxib. Studies in animals have shown reproductive toxicity. The potential for human risk in pregnancy is unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Etoricoxib is contraindicated in pregnancy. If a woman becomes pregnant during treatment, etoricoxib must be discontinued.</p><p><strong><em>Breastfeeding</em></strong></p><p>It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use etoricoxib must not breast feed.</p><p><em>Fertility</em></p><p>The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking <strong>ATOXIA<sup>&reg;</sup> 90mg F/C Tablets </strong>should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects were reported in patients with OA, RA, chronic low back pain or ankylosing spondylitis treated with etoricoxib (see Table 1):</p><p><strong>Table 1:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Experience Term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top"><p>alveolar osteitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gastroenteritis, upper respiratory infection, urinary tract infection</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p>anaemia (primarily associated with gastrointestinal bleeding), leukopenia, thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top"><p>hypersensitivity<sup>&nbsp;&szlig;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angioedema/anaphylactic /anaphylactoid reactions including shock</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p>oedema/fluid retention</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>appetite increase or decrease, weight gain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p>anxiety, depression, mental acuity decreased, hallucinations</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>confusion<em>, </em>restlessness</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top"><p>dizziness, headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dysgeusia, insomnia, paresthaesia/hypaesthesia, somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top"><p>blurred vision, conjunctivitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p>tinnitus, vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p>palpitations, arrhythmia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>atrial fibrillation, tachycardia<em>, </em>congestive heart failure, non-specific ECG changes, angina pectoris, myocardial infarction<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>flushing, cerebrovascular accident<sup>&sect;</sup>, transient ischaemic attack, hypertensive crisis<em>, </em>vasculitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p>bronchospasm</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cough, dyspnoea, epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal distention, bowel movement pattern change, dry mouth, gastroduodenal ulcer, peptic ulcers including gastrointestinal perforation and bleeding, irritable bowel syndrome, pancreatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top"><p>ALT increased, AST increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic failure, jaundice</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>ecchymosis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>facial oedema, pruritus, rash, erythema, urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, fixed drug eruption</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeletal and connective tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>muscular cramp/spasm, musculoskeletal pain/stiffness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top"><p>proteinuria, serum creatinine increased, renal failure/renal insufficiency</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top"><p>asthenia/fatigue, flu-like disease</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>blood urea nitrogen increased, creatine phosphokinase increased, hyperkalaemia, uric acid increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood sodium decreased</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).</p><p><sup>&szlig;</sup> Hypersensitivity includes the terms &quot;allergy&quot;, &quot;drug allergy&quot;, &quot;drug hypersensitivity&quot;, &quot;hypersensitivity&quot;, &quot;hypersensitivity NOS&quot;, &quot;hypersensitivity reaction&quot; and &quot;nonspecific allergy&quot;.</p><p><sup>&sect;</sup>Based on analyses of long-term placebo and active controlled clinical trials, selective COX-2 inhibitors have been associated with an increased risk of serious thrombotic arterial events, including myocardial infarction and stroke. The absolute risk increase for such events is unlikely to exceed 1% per year based on existing data (uncommon).</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>-&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms:</strong></p><p>Administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. There have been reports of acute overdosage with etoricoxib, although adverse experiences were not reported in the majority of cases. The most frequently observed adverse experiences were consistent with the safety profile for etoricoxib (e.g. gastrointestinal events, cardiorenal events).</p><p><strong>Management:</strong></p><p>In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive therapy, if required.</p><p>Etoricoxib is not dialysable by haemodialysis; it is not known whether etoricoxib is dialysable by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pharmacotherapeutic group:</em></strong><em> Anti-inflammatory and antirheumatic products, non-steroids, coxibs, </em>ATC Code: MO1 AH05</p><ul><li><strong>Mechanism of Action:</strong></li></ul><p>Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose range.</p><p>Across clinical pharmacology, Etoricoxib produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.</p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.</p><ul><li><strong>Clinical efficacy and safety:</strong></li></ul><p><strong><u>Efficacy</u></strong></p><p><strong>In acute gouty arthritis, Pain relief was observed as early as four hours after initiation of treatment. </strong></p><p>In patients with osteoarthritis (OA), etoricoxib 60 mg once daily provided significant improvements in pain and patient assessments of disease status. These beneficial effects were observed as early as the second day of therapy and maintained for up to 52 weeks. Studies with etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week treatment period (using similar assessments as the above studies). In a dose ranging study, etoricoxib 60 mg demonstrated significantly greater improvement than 30 mg for all 3 primary endpoints over 6 weeks of treatment. The 30 mg dose has not been studied in osteoarthritis of hands.</p><p>&nbsp;</p><p>In patients with rheumatoid arthritis (RA), etoricoxib 90 mg once daily provided significant improvements in pain, inflammation, and mobility. These beneficial effects were maintained over the 12-week treatment periods.</p><p>In patients experiencing attacks of acute gouty arthritis, etoricoxib 120 mg once daily over an eight-day treatment period, relieved moderate to extreme joint pain and inflammation comparable to indomethacin 50 mg three times daily. Pain relief was observed as early as four hours after initiation of treatment.</p><p>In patients with ankylosing spondylitis, etoricoxib 90 mg once daily provided significant improvements in spine pain, inflammation, stiffness and function. The clinical benefit of etoricoxib was observed as early as the second day of therapy after initiation of treatment and was maintained throughout the 52-week treatment period.</p><p>In a clinical study evaluating postoperative dental pain, etoricoxib 90 mg was administered once daily for up to three days. In the subgroup of patients with moderate pain at baseline, etoricoxib 90 mg demonstrated a similar analgesic effect to that of ibuprofen 600 mg (16.11 vs. 16.39; P=0.722), and greater than that of paracetamol/codeine 600 mg/60 mg as measured by total pain relief over the first 6 hours (TOPAR6). The proportion of patients reporting rescue medication usage within the first 24 hours of dosing was 40.8% for etoricoxib 90 mg, 25.5% for ibuprofen 600 mg Q6h, and 46.7% for paracetamol/codeine 600 mg/60 mg Q6h compared to 76.2% for placebo. In this study, the median onset of action (perceptible pain relief) of 90 mg etoricoxib was 28 minutes after dosing.</p><p><strong><u>Safety</u></strong></p><p><strong>Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme</strong></p><p>The MEDAL Programme was a prospectively designed Cardiovascular (CV) Safety Outcomes Programme.</p><p>Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline. Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. Use of gastroprotective agents and low dose aspirin were permitted in the studies.</p><p><strong>Overall Safety:</strong></p><p>There was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events. Cardiorenal adverse events were observed more frequently with etoricoxib than with diclofenac, and this effect was dose-dependent. Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib. The adverse experiences considered serious or resulting in discontinuation in the MEDAL study was higher with etoricoxib than diclofenac.</p><p><strong>Cardiovascular safety results:</strong></p><p>The rate of confirmed thrombotic cardiovascular serious adverse events (consisting of cardiac, cerebrovascular, and peripheral vascular events) was comparable between etoricoxib and diclofenac, and data are summarized in the table below. There were no statistically significant differences in thrombotic event rates between etoricoxib and diclofenac across all subgroups analyzed including patient categories across a range of baseline cardiovascular risk. When considered separately, the relative risks for confirmed thrombotic cardiovascular serious adverse events with etoricoxib 60 mg or 90 mg compared with diclofenac 150mg were similar.</p><p>CV mortality, as well as overall mortality, was similar between the etoricoxib and diclofenac treatment groups.</p><p><strong>Cardiorenal Events:</strong></p><p>The incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac. The incidence of congestive heart failure adverse events (discontinuations and serious events) occurred at similar rates on etoricoxib 60 mg compared to diclofenac 150 mg but was higher for etoricoxib 90 mg compared to diclofenac 150 mg (statistically significant for 90 mg etoricoxib vs. 150 mg diclofenac in MEDAL OA cohort). The incidence of confirmed congestive heart failure adverse events (events that were serious and resulted in hospitalisation or a visit to an emergency department) was non-significantly higher with etoricoxib than diclofenac 150 mg, and this effect was dose-dependent. The incidence of discontinuations due to edema-related adverse events was higher for etoricoxib than diclofenac 150 mg, and this effect was dose-dependent (statistically significant for etoricoxib 90 mg, but not for etoricoxib 60 mg).</p><p>In the individual MEDAL Programme, for etoricoxib (60 mg or 90 mg), the absolute incidence of discontinuation in any treatment group was up to 2.6% for hypertension, up to 1.9% for oedema, and up to 1.1% for congestive heart failure, with higher rates of discontinuation observed with etoricoxib 90 mg than etoricoxib 60 mg.</p><p><strong>MEDAL Programme Gastrointestinal Tolerability Results:</strong></p><p>A significantly lower rate of discontinuations of treatment for any clinical (e.g., dyspepsia, abdominal pain, ulcer) GI adverse event was observed with etoricoxib compared with diclofenac within each of the three component studies of the MEDAL Programme.</p><p><strong>MEDAL Programme Gastrointestinal Safety Results:</strong></p><p>Overall upper GI events were defined as perforations, ulcers and bleeds. The subset of overall upper GI events considered complicated included perforations, obstructions, and complicated bleeding; the subset of upper GI events considered uncomplicated included uncomplicated bleeds and uncomplicated ulcers. A significantly lower rate of overall upper GI events was observed with etoricoxib compared to diclofenac. There was no significant difference between etoricoxib and diclofenac in the rate of complicated events. For the subset of upper GI haemorrhage events (complicated and uncomplicated combined), there was no significant difference between etoricoxib and diclofenac. The upper GI benefit for etoricoxib compared with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin (approximately 33% of patients).</p><p>The rates of confirmed lower GI clinical events (small or large bowel perforation, obstruction, or haemorrhage, (POBs)) were not significantly different between etoricoxib and diclofenac.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>MEDAL Programme Hepatic Safety Results:</strong></p><p>Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to hepatic-related adverse experiences than diclofenac.</p><p><strong><u>Additional Thrombotic Cardiovascular Safety Data</u></strong></p><p>&nbsp;The rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen 500 mg twice daily.The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and selective COX-2 inhibitors may be of clinical significance in patients at risk of thrombo-embolic events. Selective COX-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane. The clinical relevance of these observations has not been established.</p><p><strong><u>Additional Gastrointestinal Safety Data</u></strong></p><p>The cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily. Etoricoxib had a higher incidence of ulceration.</p><p><strong><u>Renal Function in the Elderly</u></strong></p><p>Etoricoxib, celecoxib, and naproxen had similar effects on urinary sodium excretion over the 2 weeks of treatment. All active comparators showed an increase relative to placebo with respect to systolic blood pressures; however,Etoricoxib was associated with a statistically significant increase at Day 14 when compared to celecoxib and naproxen (mean change from baseline for systolic blood pressure: etoricoxib 7.7 mmHg, celecoxib 2.4 mmHg, naproxen 3.6 mmHg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li><strong><em>Absorption:</em></strong></li></ul><p>Orally administered etoricoxib is well absorbed. The absolute bioavailability is approximately 100%. Following 120 mg once-daily dosing to steady state, the peak plasma concentration (geometric mean C<sub>max</sub> = 3.6 &micro;g/ml) was observed at approximately 1 hour (T<sub>max</sub>) after administration to fasted adults. The geometric mean area under the curve (AUC<sub>0-24hr</sub>) was 37.8 &micro;g&bull;hr/ml. The pharmacokinetics of etoricoxib are linear across the clinical dose range.</p><p>Dosing with food (a high-fat meal) had no effect on the extent of absorption of etoricoxib after administration of a 120-mg dose. The rate of absorption was affected, resulting in a 36% decrease in C<sub>max</sub> and an increase in T<sub>max</sub> by 2 hours. These data are not considered clinically significant. etoricoxib was administered without regard to food intake.</p><ul><li><strong><em>Distribution:</em></strong></li></ul><p>Etoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 &micro;g/ml. The volume of distribution at steady state (V<sub>dss</sub>) was approximately 120 l in humans.</p><p>Etoricoxib crosses the placenta in rats and rabbits, and the blood-brain barrier in rats.</p><ul><li><strong><em>Metabolism:</em></strong></li></ul><p>Etoricoxib is extensively metabolised with &lt;1% of a dose recovered in urine as the parent drug. The major route of metabolism to form the 6&#39;-hydroxymethyl derivative is catalyzed by CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib <em>in vivo</em>. <em>In vitro</em> studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles <em>in vivo</em> have not been studied.</p><p>Five metabolites have been identified in man. The principal metabolite is the 6&#39;-carboxylic acid derivative of etoricoxib formed by further oxidation of the 6&#39;-hydroxymethyl derivative. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors. None of these metabolites inhibit COX-1.</p><p><strong><em>Elimination:</em></strong></p><p>In urine and 20% in faeces, mostly as metabolites. Less than 2% was recovered as unchanged drug.</p><p>Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion. Steady state concentrations of etoricoxib are reached within seven days of once daily administration of 120 mg, with an accumulation ratio of approximately 2, corresponding to a half-life of approximately 22 hours. The plasma clearance after a 25-mg intravenous dose is estimated to be approximately 50 ml/min.</p><ul><li><strong><em>Characteristics in patients</em></strong></li></ul><p><em>Elderly: </em>Pharmacokinetics in the elderly (65 years of age and older) are similar to those in the young.</p><p><em>Gender:</em> The pharmacokinetics of etoricoxib are similar between men and women.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment:</em>&nbsp;Patients with mild hepatic dysfunction (Child-Pugh score 5-6) administered etoricoxib 60 mg once daily had an approximately 16% higher mean AUC.&nbsp; Patients with moderate hepatic dysfunction (Child-Pugh score 7-9) administered etoricoxib 60 mg&nbsp;<strong><em>every other day</em></strong>&nbsp;had similar mean AUC to the healthy subjects given etoricoxib 60 mg once daily; etoricoxib 30 mg once daily has not been studied in this population. There are no clinical or pharmacokinetic data in patients with severe hepatic dysfunction (Child-Pugh score &ge;10).</p><p><em>&nbsp;</em></p><p><em>Renal impairment:&nbsp;</em>The pharmacokinetics of a single dose of etoricoxib 120 mg in patients with moderate to severe renal insufficiency and patients with end-stage renal disease on haemodialysis were not significantly different from those in healthy subjects. Haemodialysis contributed negligibly to elimination (dialysis clearance approximately 50 ml/min).</p><p><em>&nbsp;</em></p><p><em>Paediatric patients:</em>&nbsp;The pharmacokinetics of etoricoxib in paediatric patients (&lt;12 years old) have not been studied.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical studies, etoricoxib has been demonstrated not to be genotoxic. Hepatocellular and thyroid follicular cell adenomas observed in rats are considered to be a consequence of rat-specific mechanism related to hepatic CYP enzyme induction. Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in humans.</p><p>In the rat, gastrointestinal toxicity of etoricoxib increased with dose and exposure time. In the 14-week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those seen in man at the therapeutic dose. Etoricoxib was not teratogenic in reproductive toxicity studies conducted in rats at 15 mg/kg/day&nbsp; In rabbits, a treatment related increase in cardiovascular malformations was observed at exposure levels below the clinical exposure at the daily human dose (90mg). However no treatment-related external or skeletal foetal malformations were observed. In rats and rabbits, there was a dose dependent increase in post implantation loss at exposures greater than or equal to 1.5 times the human exposure</p><p>Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold those in plasma. There was a decrease in pup body weight following exposure of pups to milk from dams administered etoricoxib during lactation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><ul><li>&nbsp;Calcium hydrogen phosphate anhydrous</li></ul></td></tr><tr><td><ul><li>&nbsp;Microcrystalline Cellulose</li></ul></td></tr><tr><td><ul><li>Croscarmellose Sodium</li></ul></td></tr><tr><td><ul><li>Colloidal Silicon Dioxide</li></ul></td></tr><tr><td><ul><li>Magnesium Stearate</li></ul></td></tr><tr><td><ul><li>Opadry white Y-1-7000</li></ul></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Don&rsquo;t store above 30<sup>o</sup>C<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATOXIA<sup>&reg;</sup></strong> 90 mg F/C Tablets are packed in blisters of Aluminum / Aluminum foil, in carton box with a folded leaflet in pack size of 10 F/C tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma 
Almuraba Area 
Prince Abdulaziz bin Musaid bin Jalawi street, Mansour Alrusais Building - F1 
Riyadh-KSA
Tel: 00966114010606 
Fax: 00966114010606 
E-mail: Albaraa.bahhari@mspharma.com      

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>